Navigation Links
Moderna Therapeutics Appoints Theo Melas-Kyriazi to Board of Directors
Date:12/17/2013

CAMBRIDGE, Mass., Dec. 17, 2013 /PRNewswire/ -- Moderna Therapeutics, the pioneer in developing messenger RNA (mRNA) Therapeutics™, a revolutionary new treatment modality to enable the in vivo production of therapeutic proteins, announced today that Theo Melas-Kyriazi, CFO of Levitronix Technologies LLC and a director of Valeant Pharmaceuticals International (NYSE: VRX and TSX: VRX) has joined Moderna's board of directors.

Melas-Kyriazi brings extensive financial and executive leadership experience to Moderna, having previously served as CFO and vice president of corporate strategy for Thermo Electron Corporation (now Thermo Fisher Scientific). He also has experience as CEO of Thermo Spectra Corporation, a former subsidiary of Thermo Electron, and as a board member and investor in several early stage health sciences companies. Melas-Kyriazi joins Moderna's board as the company embarks on the next phase of its growth strategy focused on clinical development and building the world's leading mRNA platform.  

"I am thrilled that Theo is joining the Moderna board of directors. He brings important expertise and skill to the company as we scale up to build the leader in mRNA therapeutics," said Stephane Bancel, president and founding CEO of Moderna. "With his experience as CFO of Thermo Electron, a large, public life sciences company, and as a director of Valeant for the last ten years, during a period of extraordinary growth, he will be a tremendous asset to help guide Moderna's future growth."

"I am truly excited to be joining the board of Moderna, a company with tremendous potential to transform drug development," said Melas-Kyriazi. "Moderna's novel platform and ambitious vision stands out among early biotechnology leaders, and I look forward to helping the company deliver on its mission to improve the lives of patients across a broad range of diseases."

About Moderna Therapeutics

Moderna is pioneering messenger RNA Therapeutics™, an entirely new in vivo drug modality that produces human proteins or antibodies inside patient cells, which are in turn active intracellularly or secreted. This breakthrough platform addresses currently undruggable targets and offers a superior alternative to existing drug modalities for a wide range of disease conditions. Moderna has developed a broad intellectual property estate, including more than 200 patent applications with more than 10,000 claims ranging from novel nucleotide chemistries to specific drug compositions. The company plans to develop and commercialize its innovative mRNA drugs—initially for rare diseases and oncology—while partnering drug candidates in other therapeutic areas in order to rapidly deliver this innovation to patients. Moderna is a privately held company based in Cambridge, Massachusetts. Visit www.modernatx.com to learn more.

For information contact:
Maria Favorito
617-761-6720
Maria.Favorito@fkhealth.com


'/>"/>
SOURCE Moderna Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Henri A. Termeer Joins Moderna Therapeutics Board Of Directors
2. Industry Leader John Reynders Joins Moderna Therapeutics as Chief Information Officer
3. Biotech Industry Veteran Joseph Bolen Joins Moderna Therapeutics to be President of Research and Development
4. Study Published in Nature Biotechnology Demonstrates Ability of Modernas Novel Therapeutic Paradigm to Repair and Regenerate Damaged Heart Tissue
5. Moderna Therapeutics Named a "Fierce 15" Biotech Company for 2013
6. Moderna Therapeutics Named to the World Economic Forums Community of "Global Growth Companies"
7. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
8. Nile Therapeutics Reports 2011 Third Quarter Financial Results
9. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
10. Fate Therapeutics Strengthens Its iPSC Platform
11. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)...  The Biodesign Challenge (BDC), a university competition that ... living systems and biotechnology, announced its winning teams at ... New York City . The teams, ... at MoMA,s Celeste Bartos Theater during the daylong summit. ... curator of architecture and design, and Suzanne Lee ...
(Date:6/23/2016)... June 23, 2016 Apellis Pharmaceuticals, Inc. ... clinical trials of its complement C3 inhibitor, APL-2. ... multiple ascending dose studies designed to assess the ... subcutaneous injection in healthy adult volunteers. ... as a single dose (ranging from 45 to ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... and technical consulting, provides a free webinar on Performing Quality Investigations: ... 2016 at 12pm CT at no charge. , Incomplete investigations are still a ...
Breaking Biology Technology:
(Date:5/16/2016)... YORK , May 16, 2016   EyeLock ... solutions, today announced the opening of an IoT Center ... to strengthen and expand the development of embedded iris ... an unprecedented level of convenience and security with unmatched ... authenticate one,s identity aside from DNA. EyeLock,s platform uses ...
(Date:5/9/2016)... UAE, May 9, 2016 Elevay ... comes to expanding freedom for high net worth professionals ... in today,s globally connected world, there is still no ... could ever duplicate sealing your deal with a firm ... passports by taking advantage of citizenship via investment programs ...
(Date:4/28/2016)... and BANGALORE, India , April 28, 2016 ... a product subsidiary of Infosys (NYSE: INFY ), ... a global partnership that will provide end customers ... mobile banking and payment services.      (Logo: ... innovation area for financial services, but it also plays a ...
Breaking Biology News(10 mins):